Omega Therapeutics, Inc. (OMGA) NASDAQ

0.14

+0(+0.00%)

Updated at February 24 04:00PM

Currency In USD

Omega Therapeutics, Inc.

Address

20 Acorn Park Drive

Cambridge, MA 02140

United States of America

Phone

617 949 4360

Sector

Healthcare

Industry

Biotechnology

Employees

93

First IPO Date

July 30, 2021

Key Executives

NameTitlePayYear Born
Dr. Kaan Certel Ph.D.President, Chief Executive Officer & Director0N/A
Dr. David A. Berry M.D., Ph.D.Founder20,3311978
Ms. Eva StroynowskiSenior Vice President of Investor Relations & Corporate Affairs0N/A
Mr. Anthony MullinChief People Officer0N/A
Dr. Jennifer Nelson Ph.D.Chief Scientific Officer0N/A
Mr. Charles O'Donnell Ph.D.Vice President and Head of Computational Genomics & Data Sciences0N/A
Dr. Joe Newman Ph.D.Senior Vice President of Early Discovery0N/A
Ms. Barbara Y. Chan CPAPrincipal Financial Office, Principal Accounting Officer & Chief Accounting Officer01964

Description

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.